A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Does PD1/PDL1 Immunotherapy Require Patient Tumor Subgroup Pre-Analysis in the Era of Precision Medicine?
2018
Journal of Molecular and Clinical Medicine
Inter-individual variability of the therapeutic response of patients with cancer to anti-PD1 immunotherapy is a determinant for precision medicine. Anti-PD1 monoclonal antibodies (mAb) interact with the PD1 receptor expressed on T cells, hence preventing the recognition of PDL1 ligand on tumor cells and enhancing their cytotoxic effect. The Food & Drug Administration (FDA) as well as the European Medicines Agency (EMA) have approved anti-PD1 mAb for several human cancer therapies, including
doi:10.31083/j.jmcm.2018.01.007
fatcat:tzdgkranvbavjpbzt7dnxztm3e